2022 World Conference on Lung Cancer (ePosters)-EP08.02-048. Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial

EP08.02-048. Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial

Back to course

Pdf Summary

A study called METROS investigated the efficacy of the drug crizotinib in patients with ROS1 non-small cell lung cancer (NSCLC) who had brain metastases (BM). The study included a total of 64 patients with ROS1 NSCLC, of which 17 had BM at the beginning of the study. The median progression-free survival (PFS) for all patients was 13.8 months, and the median overall survival (OS) was 40.5 months. Among patients with BM, the brain was a site of disease progression for all patients, while in patients without BM, 34.0% experienced progression in the brain. The median PFS was 6.8 months in patients with BM compared to 17.4 months in those without BM. The median OS was 16.4 months in patients with BM compared to 42.8 months in patients without BM. <br /><br />These findings suggest that crizotinib is effective in treating ROS1 NSCLC, but patients with BM have a higher risk of disease progression and death. This highlights the need for drugs that can penetrate the brain to better manage ROS1 NSCLC. The study's analysis of biomarkers is still ongoing. The safety profile of crizotinib in this study was consistent with previous reports, with no new safety signals reported. No neurological adverse events or seizures were observed. Among patients with BM, 13 had Grade 3 adverse events.<br /><br />Overall, the study confirms the efficacy of crizotinib in ROS1 NSCLC and underscores the importance of considering brain penetrance in the treatment of this disease.

Asset Subtitle

Federico Cappuzzo

Meta Tag

Speaker Federico Cappuzzo

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

METROS

drug crizotinib

ROS1 non-small cell lung cancer

brain metastases

progression-free survival

overall survival

disease progression

biomarkers

safety profile

brain penetrance